Hepatitis B

AAP: Hepatitis B vaccine should be given within first 24 hours of life

AAP: Hepatitis B vaccine should be given within first 24 hours of life

The American Academy of Pediatrics recommends that the first dose of the hepatitis B vaccine should be given within the first 24 hours of life.

Telbivudine prevents hepatitis B transmission during early pregnancy

Telbivudine prevents hepatitis B transmission during early pregnancy

Telbivudine administered during early and middle pregnancy prevented hepatitis B transmission from mother to infants in all participants receiving antiviral treatment.

Blood-borne viruses more common in patients with severe mental illness

Blood-borne viruses more common in patients with severe mental illness

By

HIV, hepatitis B, and hepatitis C infections are more common among individuals with severe mental illness.

Hepatitis B vaccine reduces risk of non-Hodgkin lymphoma in adolescents

Hepatitis B vaccine reduces risk of non-Hodgkin lymphoma in adolescents

The universal vaccination against hepatitis B virus infection prevented non-Hodgkin lymphoma in adolescents.

Tenofovir prevents prenatal transmission of HBV in pregnancy

Tenofovir prevents prenatal transmission of HBV in pregnancy

Pregnant women with a high hepatitis B viral load who receive tenofovir have a reduced risk for passing the virus to their child.

EASL releases updated guidelines for managing hepatitis B virus infection

EASL releases updated guidelines for managing hepatitis B virus infection

The updated guidelines include substantial changes in the management of hepatitis B based on the latest scientific evidence.

Statins may lower risk of cirrhosis decompensation in HBV and HCV

Statins may lower risk of cirrhosis decompensation in HBV and HCV

Statin use decreased rates of decompensation in patients with liver cirrhosis due to HBV and HCV infections and in patients with alcohol-induced cirrhosis.

NASEM report aims to eliminate hepatitis B and C by 2030

NASEM report aims to eliminate hepatitis B and C by 2030

By

Aggressive testing, diagnosis, treatment, and prevention methods, such as needle exchange for those who inject drugs, are some of the options that the NASEM explored to target hepatitis elimination.

HBV and HCV coinfection increases non-Hodgkin risk in ART-treated HIV

HBV and HCV coinfection increases non-Hodgkin risk in ART-treated HIV

Patients with HIV receiving antiretroviral treatment have a higher risk of non-Hodgkin's lymphoma with HBV and HCV coinfection.

FDA requires black box warning on HCV drugs regarding potential HBV reactivation

FDA requires black box warning on HCV drugs regarding potential HBV reactivation

By

The FDA issues a warning about the risk of hepatitis B virus reactivation among patients taking direct-acting antivirals to treat hepatitis C infections.

Missed blood test results

Missed blood test results

By

A patient's positive hepatitis B results were overlooked for 7 years.

New hepatology rotation increases knowledge of liver disease among residents

New hepatology rotation increases knowledge of liver disease among residents

A new hepatology rotation increased the mean comfort level for managing several liver diseases.

Biologic agents associated with high risk of hepatitis B virus flares in patients with psoriasis or rheumatoid arthritis

Biologic agents associated with high risk of hepatitis B virus flares in patients with psoriasis or rheumatoid arthritis

The use of biologic agents in treatment of patients rheumatoid arthritis or psoriasis is associated with a significant risk of heptatis B flares.

Sign Up for Free e-newsletters